Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $72.00 price objective on the biopharmaceutical company’s stock. A number of other analysts also recently weighed in on CYTK. Bank of America reduced their target price […]